Literature DB >> 17094460

IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.

Maria Rosaria Cardillo1, Flora Ippoliti.   

Abstract

The interleukins (IL)-6 and -10 and heat shock proteins (HSP) have an important role in the host-tumor interaction and in tumor bulk. HSP-90 may have a regulatory role in cytokine biosynthesis and prognostic value in some tumors. To define the role of IL-6, IL-10 and HSP-90 in prostate cancer progression the immunohistochemical expressions of these proteins were analyzed in 168 prostatic carcinomas. IL-6, IL-10 and HSP-90 immunoreactivity was higher in prostatic carcinoma (CaP) and intra-epithelial prostatic neoplasia (PIN) than in normal prostatic tissue (NAP) adjacent to neoplasia. In the epithelium, IL-6, IL-10 and HSP-90 expressions increased from NAP to PIN to CaP. In the stroma, IL-6 and IL-10 expressions decreased significantly from NAP to PIN to CaP (p < 0.01 by Chi-square test), while HSP-90 expression increased. In the epithelium of PIN and CaP, IL-6 immunoreactivity was significantly lower than IL-10 and HSP-90. In neoplastic acini HSP-90 levels were significantly higher than those of IL-6 and IL-10 (p < 0.01 by Chi-square test). In the stroma of NAP and PIN, but not of CaP, HSP-90 immunoreactivity was significantly lower than that of IL-6 and IL-10 (p < 0.01). Our results indicate that the IL-6 and IL-10 cytokine balance differs in pathological and normal prostate, thus suggesting that certain cytokines are specific to the neoplastic prostate. Changes in the expressions of IL-6, IL-10 and HSP-90 in human prostate carcinoma samples could be used as a prognostic marker of disease progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17094460

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival.

Authors:  Haruhisa Kitano; Shun-Ichiro Kageyama; Stephen M Hewitt; Ryuji Hayashi; Yoshinori Doki; Yoshitomo Ozaki; Shozo Fujino; Mikiko Takikita; Hajime Kubo; Junya Fukuoka
Journal:  Arch Pathol Lab Med       Date:  2010-10       Impact factor: 5.534

Review 2.  Are androgen receptor variants a substitute for the full-length receptor?

Authors:  Ji Lu; Travis Van der Steen; Donald J Tindall
Journal:  Nat Rev Urol       Date:  2015-02-10       Impact factor: 14.432

3.  Delivery of HSP90 Inhibitor Using Water Soluble Polymeric Conjugates with High Drug Payload.

Authors:  Jose A Suárez Del Pino; Rohit Kolhatkar
Journal:  Pharm Res       Date:  2017-09-14       Impact factor: 4.200

Review 4.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

5.  Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.

Authors:  Nishant Gandhi; Aaron T Wild; Sivarajan T Chettiar; Khaled Aziz; Yoshinori Kato; Rajendra P Gajula; Russell D Williams; Jessica A Cades; Anvesh Annadanam; Danny Song; Yonggang Zhang; Russell K Hales; Joseph M Herman; Elwood Armour; Theodore L DeWeese; Edward M Schaeffer; Phuoc T Tran
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

Review 6.  Steroid Receptor-Associated Immunophilins: A Gateway to Steroid Signalling.

Authors:  Thomas Ratajczak; Carmel Cluning; Bryan K Ward
Journal:  Clin Biochem Rev       Date:  2015-05

7.  Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.

Authors:  Elizabeth V Nguyen; Margaret M Centenera; Max Moldovan; Rajdeep Das; Swati Irani; Andrew D Vincent; Howard Chan; Lisa G Horvath; David J Lynn; Roger J Daly; Lisa M Butler
Journal:  Mol Cell Proteomics       Date:  2018-04-09       Impact factor: 5.911

8.  Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model.

Authors:  Angeline A Giangreco; Shweta Dambal; Dennis Wagner; Theodorus Van der Kwast; Reinhold Vieth; Gail S Prins; Larisa Nonn
Journal:  J Steroid Biochem Mol Biol       Date:  2014-10-08       Impact factor: 4.292

9.  A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.

Authors:  Manish K Thakur; Lance K Heilbrun; Shijie Sheng; Mark Stein; Glenn Liu; Emmanuel S Antonarakis; Ulka Vaishampayan; Sijana H Dzinic; Xiaohua Li; Stacy Freeman; Daryn Smith; Elisabeth I Heath
Journal:  Invest New Drugs       Date:  2015-11-18       Impact factor: 3.850

10.  High-throughput microfluidic 3D biomimetic model enabling quantitative description of the human breast tumor microenvironment.

Authors:  Ilana Berger Fridman; James Kostas; Michal Gregus; Somak Ray; Matthew R Sullivan; Alexander R Ivanov; Smadar Cohen; Tania Konry
Journal:  Acta Biomater       Date:  2021-06-18       Impact factor: 10.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.